ReviewFEBS open bio2025
Liver-specific lncRNAs associated with liver cancers.
Review in FEBS open bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A step further in our commitment to support early career researchers (ECRs).FEBS open bio · 2026Article
- Non-coding RNAs as key player in cancer diagnosis and treatment.FEBS open bio · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Long non-coding RNAs (lncRNAs) are transcripts with a length more than 200 nt, which do not encode proteins and act just as RNA molecules. In general, lncRNAs have much more distinct tissue specificity than proteins, as they usually realize more peculiar regulatory functions. Their expression levels are often altered in a response to stress conditions, metabolic changes, development of different diseases, and carcinogenesis. Cancer-associated lncRNAs are widely considered as perspective and useful biomarkers. Thus, development of clinical tests, which include tissue-specific and cancer-specific lncRNAs, might significantly contribute to cancer diagnostics and/or prognosis of the disease. A number of lncRNAs is known to be dysregulated in liver tumors and considered as probable biomarkers. However, most of them are rather universally well-known lncRNAs associated with various cancers. In the present review, we aimed to shed light on other lncRNAs with preferential expression in liver and/or liver tumors, for example, LINC01554, LINC01093, LINC01348, LINC02428, FAM99B, etc. We summarized recent discoveries unveiling their dysregulation in liver malignancies and related cellular mechanisms in which they are involved and considered their significance as probable liver cancer biomarkers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.